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Abstract
Objective: The objectives of this study were to investigate whether the plasma levels of oligomeric amyloid-β (OAβ)
were affected in Alzheimer’s disease (AD) and to examine the associations (or possible correlations) between plasma
OAβ levels and memory performance.
Method: Thirty subjects with AD and 28 cognitively normal controls were recruited in the study. The multimer
detection system (MDS) was used to measure the levels of OAβ in the plasma. In addition to assessing the general
cognitive function with the Mini-Mental State Examination (MMSE), Cognitive Abilities Screening Instrument (CASI), and
Alzheimer’s Disease Assessment Scale–cognitive portion (ADAS-Cog), the common objects memory test (COMT) was
used to examine the episodic memory performance. Pearson’s and partial correlation analyses were conducted to
explore the associations between cognitive performance and OAβ levels in the plasma. A receiving operating
curve (ROC) analysis was used to discriminate between the AD and control groups.
Results: The plasma OAβ levels in the AD group were significantly higher than those in the control group [1.88
(0.38) ng/ml vs 1.20 (0.40) ng/ml, p < 0.001]. The elevated levels of plasma OAβ showed a strong correlation with
cognitive performance in patients with AD, including an inverse correlation with scores on the MMSE (r = − 0.43,
p = 0.02), CASI (r = − 0.56, p < 0.01), and the immediate recall (r = − 0.45, p = 0.01), 5-min delayed recall (r = − 0.56,
p < 0.01), and 30-min delayed recall (r = − 0.71, p < 0.001) tests of the COMT, and a positive correlation with the
ADAS-Cog scores (r = 0.59, p < 0.001). The EDTA plasma Aβ oligomer optical density (OD) value measured using
the MDS could discriminate between the AD and control groups with an area under the curve (AUC) of 0.89. The
optimal sensitivity and specificity were 82.1% and 90.0%, respectively.
Conclusion: The elevated levels of OAβ in the plasma distinguished the AD and control groups and were associated
with the severity of symptoms, especially memory performance, in patients with AD. Our results suggested that plasma
OAβ could potentially be a simple and non-invasive blood-based biomarker for AD diagnosis. Furthermore,
longitudinal studies are warranted to explore the application of plasma OAβ levels as a valid diagnostic biomarker in
patients with AD.
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Introduction
The amyloid cascade hypothesis suggests that Alzheimer’s
disease (AD) results from the imbalance between the pro-
duction and clearance of amyloid-β (Aβ) [1]. The imbal-
ance could lead to the accumulation and oligomerization
of Aβ42 in the limbic and association cortices. Currently,
Aβ oligomers are widely recognized as the most toxic and
pathogenic forms of Aβ. The oligomerization of Aβ (OAβ)
would be triggered from conformational alterations of the
monomeric Aβ. The low-molecular-weight dimers and tri-
mers could aggregate and form soluble oligomers and
then high-molecular-weight oligomers, which would even-
tually evolve into insoluble fibrils. Previous experiments
have shown that OAβ may trigger neuronal toxicity and
synaptic loss. In the transgenic AD mouse model, OAβ
levels in the brain, rather than total amyloid plaque accu-
mulation, correlated closely with neuronal loss [2, 3]. Guli-
sano et al. found that OAβ could impair the long-term
potentiation and spatial memory [4]. In addition, Hou
et al. found that the inhibition of OAβ could improve
spatial learning and memory function in PS1V97L trans-
genic mice [5]. These results implied that OAβ may serve
as a potential fingerprint biomarker of memory function
in AD [6, 7].
Results from several studies have revealed that the ele-
vated OAβ levels in cerebrospinal fluid (CSF) correlated
well with cognitive decline in patients with AD [8–10]. As
the blood–brain barrier may break down in patients with
AD, the levels of OAβ in the blood could reflect patho-
logic processes in the brains of AD patients [11, 12].
Although several sources of evidence have supported
the notion that deficits in episodic memory manifest in
patients with AD [13–16], it has remained unclear
whether plasma OAβ levels would correlate with mem-
ory function in AD. Few studies have explored the po-
tential links between plasma OAβ levels and memory
performance in patients with AD. Using different
methods, such as the enzyme-linked immunosorbent
assay (ELISA), several studies have shown that OAβ
levels in the plasma or serum were associated with gen-
eral cognitive performance in patients with AD [17–19].
However, large variations in OAβ concentrations were
observed across studies. Previously, Wang et al., Yang
et al., An et al., and Youn et al. demonstrated that eleva-
tions in plasma OAβ could be monitored with the multi-
mer detection system (MDS) [19–22]. However, the
study based on the MDS has not been involved the clin-
ical relevance of the plasma OAβ in AD.
Therefore, we designed this study on the basis of previ-
ous reports by Wang et al., Yang et al., An et al., and Youn
et al. [19–22] to compare the levels of plasma OAβ be-
tween the AD and the control groups and to examine the
associations between plasma OAβ levels and memory per-
formance, including immediate and delayed recalls. We
hypothesized that the plasma OAβ level was elevated in
patients with AD and also correlated with the memory
performance in patients with AD.
Methods
Participants
From March to September 2017, 30 people with AD and
28 cognitively normal controls were recruited from the
case registry at the Dementia Care and Research Centre,
Peking University Institute of Mental Health. All research
participants were administered the neuropsychological
test battery, underwent MRI scanning, and received a
thorough blood test for measures including blood cell
count, hepatic and renal function, thyroid function, and
levels of vitamin B12 and folic acid, as well as serum syph-
ilis testing. A dementia specialist interviewed all partici-
pants prior to making each diagnosis.
The inclusion criteria for the AD group were as fol-
lows: (1) were aged between 60 and 90 years; (2) met the
criteria for dementia according to the International Clas-
sification of Diseases, 10th Revision (ICD-10) and the
criteria for probable AD of the National Institute of
Neurological and Communicative Disorders and the
Stroke/Alzheimer Disease and Related Disorders Associ-
ation (NINCDS-ADRDA); (3) had more than 6 years of
education; and (4) had a score on the modified
Hachinski ischemic scale of ≤ 4.
The inclusion criteria for the control group were as fol-
lows: (1) were aged between 60 and 90 years, (2) had more
than 6 years of education, (3) did not have memory com-
plaints, and (4) did not have detected cognitive impairment.
Individuals who had major medical problems, such as
tumors, cerebrovascular events, or psychiatric disorders,
such as depression, schizophrenia, or alcohol-related dis-
order, were excluded.
The study protocol was approved by the Institutional
Review Board of Peking University Sixth Hospital. In-
formed consent was obtained from each participant.
Neuropsychological assessment
Standardized procedures were used to administer the
neuropsychological test battery as described previously
[23]. Briefly, the overall cognitive function was assessed
with the Mini-Mental State Examination (MMSE), Cog-
nitive Abilities Screening Instrument (CASI), and Alz-
heimer’s Disease Assessment Scale–cognitive portion
(ADAS-Cog) [24–26].
The neuropsychological test battery measured specific
cognitive domains, including common objects memory
test (COMT) for episodic memory; Stroop test for ex-
ecutive function; the animal naming test for language;
read and set time, Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) drawing and block design
for visuospatial function; digit span (forward and
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backward) for attention; and picture completion for rea-
soning [27].
The present study paid particularly close attention to
COMT performance. The COMT was developed to pro-
vide a culturally sensitive measure of recent memory,
specifically for use in a cross-cultural neuropsychological
test battery. This test was administered using standard-
ized procedures, as previously described [27]. Briefly, the
participants were shown a set of ten colored pictures of
common objects (e.g., button, chair, scissors, clock,
comb, cup, key, knife, leaf, and umbrella) during three
learning trials at the rate of one picture per 2 s. The pic-
tures were spiral-bound and presented in a standard
order that differed among the three trials; the partici-
pants were required to immediately recall as many ob-
jects as possible after each learning trial. After all three
trials, the participants engaged in brief distractor tasks
(e.g., CERAD figure drawing) for 3 to 5 min and were
subsequently asked again to recall the previous objects.
This recall order was serially recorded. The 5-min de-
layed recall was immediately followed by a recognition
test, in which ten original objects were interspersed with
ten distractors. The subjects were asked to indicate with
a simple “yes” or “no” whether an item was observed in
the original three learning tests. The distractor objects
were similar to the original objects in terms of the visual
complexity and lacking distinctive details. Long-term re-
tention of the original objects was assessed after a 30-
min delay using tests of recall and recognition, with a
different set of ten distractors.
Plasma preparation
Samples were treated with heparin and EDTA to com-
pare the effects of the two anticoagulants on the OAβ
levels. Venous blood was collected in 6-ml BD Vacutai-
ner® EDTA tubes and 10-ml BD Vacutainer® heparin
tubes, followed by centrifugation at 850×g for 30 min at
room temperature (RT). The separation of plasma was
performed within 3 h of sample collection. The plasma
was aliquoted into polypropylene tubes (1.5 ml) in vol-
umes of 500 μl and stored at − 80 °C until assayed.
Quantifying the levels of plasma OAβ
The MDS-AD assay kit (donated by the PeopleBio, Inc.,
Korea) was used to quantify the levels of OAβ in the
plasma. The antibodies used in the assay kit were the
mouse monoclonal antibody 6E10 (BioLegend, San
Diego, CA, USA) and WO2-HRP antibody (Absolute
Antibody Ltd., Oxford, UK). A well-trained technician
was blind to the diagnostic information of the samples
and performed the experiments according to the manu-
facturer’s protocol [19–22]. More details of the quality
of assay are provided in Additional file 2: Table S1.
Prior to the procedure, aliquots of plasma samples were
thawed at 37 °C for 15min. Ten microliters of plasma, 4 μl
of HAMA (human anti-murine antibody, HAMA) blocker
(Scantibodies Laboratory, Santee, CA, USA), and 90 μl of
assay buffer were mixed. Ten microliters of PBR-1 (1% pro-
prietary + 1.25% dimethyl sulfoxide (DMSO) + 96.75%
phosphate-buffered saline contains Tween 20 (PBST) + 1%
ultra-pure water) was mixed into the plasma mixture. Then,
the heparin-treated plasma mixtures and EDTA-treated
plasma mixtures were incubated for 48 h and 1 h, respect-
ively. The plasma sample mixture and serially diluted stan-
dards were added to separate wells of the plate in a total
volume of 100 μl. The plates were incubated at RT for 1 h.
After washing three times with washing buffer, the detec-
tion antibody was added to the wells, and the plate was in-
cubated for 1 h at RT. Finally, 100 μl of 3, 3′, 5, 5′-
tetramethylbenzidine (TMB) reagent was added as a sub-
strate, and after 15min, the reaction was stopped with 50 μl
of 1M H2SO4. Optical density (OD) values were measured
at 450 nm using a Victor 3™ multi-spectrophotometer.
After the experiments, OD from the samples and the
standard curve were used to calculate the levels of OAβ in
the plasma. The analysis was performed for both ODs and
absolute concentration which was converted from the
ODs. We did the serially diluted standards for quality con-
trol. In our paper, R2 value of the standard curve was
about 0.99 (shown in Additional file 1: Figure S1). In
addition, we think it is better to present raw data other
than the absolute concentrations in research papers. Until
now, detecting crude oligomeric Aβ in the plasma was a
challenge, owing to its low concentrations in the blood.
MDS for AD was optimized to enhance detection by spik-
ing synthetic Aβ42 into the plasma as mentioned in a re-
cent study. Previous papers using the MDS test detected
the raw luminescence signal and used relative lumines-
cence units (RLU) to present the OAβ levels [19]. There-
fore, we chose to present the ODs as the main results.
Statistical analysis
Data analysis was performed with IBM SPSS Statistics
20.0 software. Student’s t tests were used to compare the
ages and educational levels, and the two-tailed chi-
square (χ2) tests were used to compare sex ratio and
apolipoprotein Eε4 (APOEε4) status between the AD
and control groups.
The levels of plasma OAβ and the cognitive perfor-
mances between the two groups were compared with
Student’s t tests. A linear regression model was used to
analyze the associations between the plasma OAβ levels
from the samples processed with the EDTA and heparin
anticoagulants. Next, Pearson’s correlation analysis was
performed to examine the associations between plasma
OAβ levels and cognitive test scores. A partial correl-
ation analysis adjusting for age, sex, educational level,
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and APOEε4 status was used in a subsequent investiga-
tion of the correlations. Potential group differences with
respect to the COMT memory performances were inves-
tigated with analysis of variance (ANOVA) and ANOVA
for repeated measures.
To explore the utility of OAβ in assisting the clinical
diagnosis, we computed the area under the receiving op-
erating characteristic (ROC) curve (AUC) that discrimi-
nated patients with AD from controls. All tests were
two-sided. The statistical significance was set at p < 0.05.
Results
Demographic characteristics of the research participants
As shown in Table 1, the average age in the control
group was 71.9 ± 7.2 and that in the AD group was
76.9 ± 5.8 (p = 0.006). No significant group difference
was observed in the comparison of the sex ratio or in
their educational levels (p > 0.05).
Comparison of cognitive performance in the AD and
control groups
As expected, the AD group exhibited lower performance
on overall cognitive function and the episodic memory
test than the control group (all p < 0.001, Table 2).
Specifically, the AD group presented a significant de-
crease in the number of recalled items immediately or
after the 5- and 30-min delays (p < 0.001, Table 2). Fur-
thermore, recall of the first three words (primacy effect)
(Fig. 1a) and the last three words (recency effect) (Fig. 1b)
of the COMT wordlist was lower in the AD group than
in the control group (Fig. 1).
Differences in plasma OAβ OD values between the two
groups
The plasma OAβ OD values were markedly elevated in
the AD group compared with the control group (p <
0.001 for samples anti-coagulated with either EDTA or
heparin (Fig. 2a, b). The EDTA plasma Aβ oligomer OD
value measured using the MDS could discriminate be-
tween the AD and control groups with an AUC of 0.89.
The best sensitivity and specificity levels were 82.1% and
90.0%, respectively (Fig. 2c). With the heparin-treated
samples, the MDS also showed a high sensitivity of
75.0% and specificity of 86.7% between the AD and con-
trol groups with an AUC of 0.87 (Fig. 2c).
The levels of OAβ in the EDTA-treated plasma
showed a strong direct correlation with the heparin-
treated plasma (r = 0.35, p < 0.001, see Fig. 2d). Hereafter,
the experiment was carried out using EDTA, which is
more commonly used. All of the following data were an-
alyzed using the levels of OAβ OD in the EDTA-treated
plasma. There was no effect of age, sex, or ApoE4 status
on the plasma OAβ OD values (p > 0.05, Fig. 3).
The inter-group difference in the plasma OAβ levels
remained significant (p < 0.05) after taking age into ac-
count. This result was replicated in the heparin- and
EDTA-treated plasma samples.
Correlation of plasma OAβ levels and overall cognitive
function
The plasma OAβ OD value correlated strongly with the
scores on the MMSE (r =− 0.43, p= 0.02), CASI (r=− 0.56,
p < 0.01), and ADAS-Cog (r= − 0.59, p < 0.001) in the AD
group (Fig. 4). After adjusting for age, sex, educational sta-
tus, and ApoEε4 status, the linear regression models pre-
served the significant direct correlation between the
plasma OAβ OD values and overall cognitive function
Table 1 Demographic characteristics of the study participants
AD group (n = 30) Control group (n = 28) t/χ2 p value
Age (years), mean (SD) 76.9 (5.8) 71.9 (7.2) − 2.88 0.006
Sex, M/F (n) 15/15 7/21 5.59 0.05
Education (years), mean (SD) 13.6 (2.7) 14.3 (1.9) 1.06 0.30
APOEε4 carriers (n) 16 5 7.89 0.005
The two-tailed chi-square (χ2) test was used to compare the distribution of sex and APOEε4 status in the two groups. Student’s t tests (t) were used for age and education
AD Alzheimer’s disease, SD standard deviation
Table 2 Cognitive performance in the AD and control groups
Cognitive measures AD group (n = 30) Control group (n = 28) p value
MMSE 19.6 (5. 4) 28.4 (1.3) < 0.001
CASI 72.3 (14.0) 94.2 (4.5) < 0.001
ADAS-Cog 21.2 (10.4) 4.3 (2.8) < 0.001
COMT
IR-T1 3.1 (1.7) 6.7 (1.4) < 0.001
IR-T2 4.4 (1.6) 8.4 (1.2) < 0.001
IR-T3 5.2 (1.5) 9.0 (0.9) < 0.001
DR5 2.6 (2.1) 8.4 (1.2) < 0.001
DR30 1.8 (2.0) 8.6 (1.0) < 0.001
Data are presented as the mean (SD). p values were obtained using Student’s
t tests for all data
AD Alzheimer’s disease, MMSE Mini-Mental State Examination, CASI Cognitive
Ability Screening Instrument, ADAS-Cog Alzheimer’s disease assessment scale–
cognitive portion, COMT common object memory test, IR-T1 trial #1 of the
immediate recall test, IR-T2 trial #2 of the immediate recall test, IR-T3 trial #3 of
the immediate recall test, DR5 5-min delayed recall test, DR30 30-min delayed
recall test
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Fig. 1 Common objects memory test (COMT) results for patients with Alzheimer’s disease (AD) compared with normal controls. The recall
percentage for the first three words (a) and the last three words (b) on the wordlist was lower in the AD patients than in the normal controls. IR-
T1, trial #1 of the immediate recall test; IR-T2, trial #2 of the immediate recall test; IR-T3, trial #3 of the immediate recall test; DR5, 5-min delayed
recall test; DR30, 30-min delayed recall test. *p < 0.05
Fig. 2 Effect of anticoagulants on OAβ OD values in the plasma. Comparison of the OAβ levels in patients with AD and in normal controls from
samples processed with EDTA (a) and heparin (b) anticoagulants. c ROC analysis of the plasma OAβ OD values measured using the MDS. d The
scatter plot shows the linear regression between the OAβ OD values in the plasma processed with the anticoagulant heparin (x-axis) and EDTA
(y-axis). The shaded area shows the 95% CI
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(Additional file 3: Table S2). In comparison, no significant
association between the OAβ OD values and cognitive test
scores was observed in the control group (p > 0.05).
Correlation of the plasma OAβ OD values with episodic
memory
In the AD group, significant associations were noticed
between the plasma OAβ levels and COMT immediate
(r = − 0.45, p = 0.01), 5-min (r = − 0.56, p < 0.01) and 30-
min (r = − 0.71, p < 0.001, Fig. 5) recall scores. The statis-
tical significance remained after adjusting for age, sex,
education, and ApoEε4 status (Table 3). On the other
hand, no significant associations were observed between
the plasma OAβ levels and the primacy and recency ef-
fects in the memory test (p > 0.05).
In the control group, a weak associative trend was ob-
served only between the plasma OAβ OD values and the
30-min delayed recall scores (p = 0.05) (Fig. 5c). No
significant correlation was observed between the plasma
OAβ levels and any other memory measure.
Discussion
In the present study, the levels of plasma OAβ were ele-
vated in patients with AD compared to controls. Inter-
estingly, the elevated plasma levels of OAβ strongly
correlated with the decreased general cognitive level and
deteriorated episodic memory performance in patients
with AD in comparison with healthy age-matched nor-
mal subjects. The current observations support the no-
tion that plasma OAβ could serve as a potential blood-
based biomarker for the early diagnosis of AD.
OAβ have been reported as the most neurotoxic
agents in the pathological process of AD [6]. Previous
studies have revealed that soluble OAβ in the brain were
involved in the early stages of AD pathology and predate
classic fibrillar amyloid plaque deposition, neuronal cell
Fig. 3 The effects of age, sex, and ApoEε4 status on the plasma OAβ OD values in the AD (circle) and control (triangle) groups. a The plasma
OAβ levels were not correlated with age (p > 0.05). b There was no significant difference in the plasma OAβ levels between men and women. c
There was no significant difference in the plasma OAβ levels between APOEε4 carriers and non-carriers. AD, Alzheimer’s disease
Fig. 4 The plasma OAβ OD values were significantly correlated with cognitive function. The scatter plots show the correlation of the plasma OAβ
levels with the scores on the MMSE (a), CASI (b), and ADAS-Cog (c) tests in the AD (circle and solid line) and control (triangle and dotted line)
groups. AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; CASI, Cognitive Ability Screening Instrument; ADAS-Cog, Alzheimer’s
disease assessment scale–cognitive portion
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loss, and memory impairment [28]. Other previous stud-
ies have reported elevations in OAβ levels in CSF and
brain tissue in patients with AD [8, 29, 30]. Wang et al.
demonstrated that the levels of plasma OAβ were associ-
ated with CSF levels of Aβ42, phosphorylated tau protein
(pTau), and total tau protein (tTau) [19]. The positive
correlation between the levels of OAβ detected in serum
and those in matched samples of CSF has been found by
Kasai et al. The result suggested that OAβ could diffuse
or be efficiently transported across the blood–brain or
the blood–CSF barrier (collectively referred to as the
BBB) and/or that the BBB allowed Aβ carrier proteins to
be transferred between the blood and CSF, which would
transfer Aβ peptides to the blood in the form of OAβ
complexes [31]. Our study provided the support that the
levels of OAβ in the plasma were increased in the pa-
tients with AD, which was consistent with previous re-
ports, and therefore, the increased plasma levels of OAβ
could be indicative of AD pathology.
One of the most exciting findings from the present
study was that the plasma levels of OAβ were highly cor-
related with episodic memory performance (measured
with the COMT) in addition to general cognitive func-
tion (measured with the MMSE, CASI, and ADAS-Cog).
Previous studies have demonstrated that the level of sol-
uble OAβ was correlated with the extent of synaptic loss,
which would restrict hippocampal function [28]. In-
creased levels of OAβ were also described by Fukumoto
et al. The levels of OAβ in AD or MCI patients has been
found were significantly higher than in normal controls
and correlated inversely with MMSE score. The AUC
for the OAβ (0.844) was greater than that for the CSF
Aβ42 (0.712), suggesting that OAβ may serve as a test
for discriminating between AD/MCI patients and cogni-
tively normal control [32]. The present study could be
the first to report the correlation between plasma OAβ
and episodic memory. Changes in episodic memory were
reported as one of the earliest pathological features of
AD. In various learning and recall paradigms, a delayed
recall was considered the measurable characteristic of
mild cognitive impairment and AD [24–26]. As a test
with minimal cultural bias, the COMT has been widely
used in cross-cultural assessments of memory perform-
ance [27]. The strong correlations between the plasma
levels of OAβ and the immediate and delayed recall scores
on the COMT revealed that the increased levels of plasma
OAβ paralleled the earliest cognitive changes in patients
with AD. Coupled with the relevance to the severity of de-
mentia, the significance of plasma OAβ in accordance
with the earliest cognitive changes could present add-
itional evidence in support of plasma OAβ as a potential
blood-based biomarker for AD screening or diagnosis.
Furthermore, this study demonstrated the reliability of
quantifying the OAβ in the plasma. In previous studies
by Wang et al., Yang et al., An et al., and Youn et al., the
MDS method was applied to the plasma samples with
heparin as an anticoagulant [19–22]. The present study
found that the levels of OAβ in the EDTA-treated
plasma samples were highly correlated with those in the
heparin-treated plasma samples, indicating that OAβ
Fig. 5 The plasma OAβ OD values were significantly correlated with the COMT scores in patients with AD and normal controls. The scatter plots
show the correlation of the OAβ levels with the immediate (a), 5-min (b), and 30-min (c) delayed recall scores on the COMT in the AD (circle and
solid line) and control (triangle and dotted line) groups. COMT, common object memory test; COMT-IR, immediate recall of the COMT; COMT-
DR5, 5-min delayed recall of the COMT; COMT-DR30, 30-min delayed recall of the COMT
Table 3 Correlations of plasma OAβ levels with the immediate
and delayed recall scores on the COMT after adjusting for age,
sex, educational level, and ApoEε4 status
AD (n = 30) Control (n = 28)
r p r p
Episodic memory
COMT-IR − 0.60 0.002 − 0.13 0.56
COMT-DR5 − 0.54 0.006 − 0.18 0.41
COMT-DR30 − 0.71 < 0.001 − 0.23 0.27
AD Alzheimer’s disease, COMT common object memory test, IR immediate recall
(average of three trials), DR5 5-min delayed recall, DR30 30-min delayed recall
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levels are relatively stable and independent, allowing reli-
able quantification in the plasma samples treated with
either EDTA or heparin anticoagulant.
Although the present study revealed the interesting re-
sult of OAβ levels as a potential blood-based biomarker,
our findings should be interpreted with caution and have
the following limitations: First, the study was performed
with samples collected from a cross-sectional study. Future
longitudinal studies are warranted to investigate and verify
whether plasma OAβ could monitor and/or represent dis-
ease progression. The trajectory of the OAβ levels in the
plasma could provide evidence on its clinical application as
a prognostic biomarker [28–30]. Second, we did not repli-
cate the analysis on the correlation between plasma oligo-
mer and CSF AD biomarkers reported by Wang et al. [19].
However, according to the five-phase model of biomarker
discovery proposed by Frisoni et al. [33], it is even more
important to examine the evidence of the clinical relevance
of the plasma oligomer in AD. Our exploratory clinical
assay would support future studies that will use a large
sample of longitudinal data available in the repositories to
explore the usefulness of plasma oligomer in the detection
of AD. Third, examining the profile of MCI would
strengthen the utility of oligomer as a potential biomarker
for AD. Our study was designed on the basis of the previ-
ous report by Wang et al. and aimed to examine whether
the level of oligomer was associated with the memory per-
formance [19]. A significant association indicated, to some
extent, the level of oligomer might reflect the clinical
phenotype. In addition, the lack of patients with neurode-
generative diseases other than AD, such as frontotemporal
dementia and dementia of Lewy body, would prevent our
testing for disease specificity of plasma OAβ. To the best
of our knowledge, the evidence of the blood-based bio-
markers of AD remains limited, especially when discrimin-
ating AD from other neurodegenerative diseases. Our
study explored the potential of OAβ in the plasma to dif-
ferentiate AD from normal cognition. It remains further
investigations to establish its usefulness in screening for de-
mentia. The MDS assay remained in the early phase of de-
velopment. Additional retrospective studies with a larger
sample size would be needed. Such studies have recently
been planned in Asian and European countries. Addition-
ally, further studies are needed for addressing the role of
plasma OAβ in AD detection from both neuropathological
and clinical perspective. Prospective studies on the diag-
nostic accuracy with confirmed neuropathological cases,
via MRI, amyloid PET, or CSF biomarkers, should be con-
sidered for validating the application of plasma OAβ levels
as a diagnostic biomarker.
Conclusion
The present study indicates that elevated levels of OAβ
in the plasma, which strongly correlate with symptom
severity, especially episodic memory, might be a poten-
tial biomarker for AD diagnosis. Since plasma samples
are easily obtained and MDS is simple to perform, meas-
uring OAβ in the plasma could be a potential diagnostic
screening approach in the clinical setting once the cutoff
value is determined.
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